Langzhou Song
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Langzhou Song has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
Ge Liu
VaxInnate Corporation, 3 Cedar Brook Drive, Cranbury, NJ 08512-0026, USA
3 shared publicationsHong Li
VaxInnate Corporation, 3 Cedar Brook Drive, Cranbury, NJ 08512-0026, USA
3 shared publicationsLucia Reiserova
VaxInnate Corporation, 3 Cedar Brook Drive, Cranbury, NJ 08512-0026, USA
3 shared publicationsLynda Tussey
VaxInnate Corporation, 3 Cedar Brook Drive, Cranbury, NJ 08512-0026, USA
3 shared publicationsScott Umlauf
VaxInnate Corporation, 3 Cedar Brook Drive, Cranbury, NJ 08512-0026, USA
3 shared publicationsJim Huleatt
VaxInnate Corporation, 3 Cedar Brook Drive, Cranbury, NJ 08512-0026, United States
2 shared publications
Latest Publications
- Open Access
- 21 May 2008
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 3 (5) , e2257
Efficacious Recombinant Influenza Vaccines Produced by High Yield Bacterial Expression: A Solution to Global Pandemic and Seasonal Needs
It is known that physical linkage of TLR ligands and vaccine antigens significantly enhances the immunopotency of the linked antigens. We have used this approach to generate novel influenza vaccines that fuse the globular head domain of the protective hemagglutinin (HA) antigen with the potent TLR5 ligand, flagellin. These fusion proteins are efficiently expressed in standard E. coli fermentation systems and the HA moiety can be faithfully refolded to take on the native conformation of the globular head. In mouse models of influenza infection, the vaccines elicit robust antibody responses that mitigate disease and protect mice from lethal challenge. These immunologically potent vaccines can be efficiently manufactured to support pandemic response, pre-pandemic and seasonal vaccines.
- 21 May 2008
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 3 (5) , e2257
Open AccessEfficacious Recombinant Influenza Vaccines Produced by High Yield Bacterial Expression: A Solution to Global Pandemic and Seasonal Needs
It is known that physical linkage of TLR ligands and vaccine antigens significantly enhances the immunopotency of the linked antigens. We have used this approach to generate novel influenza vaccines that fuse the globular head domain of the protective hemagglutinin (HA) antigen with the potent TLR5 ligand, flagellin. These fusion proteins are efficiently expressed in standard E. coli fermentation systems and the HA moiety can be faithfully refolded to take on the native conformation of the globular head. In mouse models of influenza infection, the vaccines elicit robust antibody responses that mitigate disease and protect mice from lethal challenge. These immunologically potent vaccines can be efficiently manufactured to support pandemic response, pre-pandemic and seasonal vaccines.